Calypte " HIV" und " AMEX"


Seite 1 von 1
Neuester Beitrag: 12.10.04 18:10
Eröffnet am:12.10.04 18:04von: LuckyStrikeAnzahl Beiträge:2
Neuester Beitrag:12.10.04 18:10von: werweißLeser gesamt:1.895
Forum:Hot-Stocks Leser heute:2
Bewertet mit:
1


 

1963 Postings, 7451 Tage LuckyStrikeCalypte " HIV" und " AMEX"

 
  
    #1
1
12.10.04 18:04
Ich dachte mir, wenn Caly schon ein neues Kürzel hat und weil Caly an der AMEX gelistet ist, sollten wir auch einen neuen Thread dafür haben!.
Vielleicht bringt es uns auch die Aufträge.!
Sollten wir das machen?
Grüße Lucky  

1544 Postings, 7730 Tage werweißUnd weiter zieht die Karawane

 
  
    #2
12.10.04 18:10
PHA Public Health Expo
Booth: 1020


Calypte Biomedical Corporation is a developer, manufacturer, and marketer of in vitro assays for HIV infection.

Calypte manufactures three FDA-approved tests for HIV-1 antibody, including an EIA and a Western Blot which are uniquely capable of determining HIV antibody status in urine samples.

Of special interest to public health authorities and epidemiologists is the Calypte HIV-1 BED Incidence EIA. Calypte manufactures this assay under license from the U.S. Centers for Disease Control and Prevention (CDC), and within the USA, the CDC also acts as the exclusive distributor for the product.

The BED Incidence EIA was developed specifically to help researchers determine how many infections in an HIV-1 seropositive population were recently acquired versus those that were acquired in the more distant past (more than 5 - 6 months previously). The BED assay provides a practical and effective way for program managers and policy makers to track the expansion of the HIV pandemic into susceptible populations, to identify those regions and the populations within those regions where HIV transmission is occurring most recently, and to focus resources on programs that have been shown to be most effective at reducing the rate of new infections.

The BED Incidence test employs a unique peptide that ensures sensitivity across all major strains of HIV-1, and operates on a different principle than previous attempts to discriminate between recent and remote infections that relied upon high dilution factors to desensitize diagnostic assays. The BED Incidence test determines the ratio of HIV-specific IgG to Total IgG in comparison to that of a calibrator which represents an infection of five months' duration.
Category: Infectious Diseases, Pharmaceutical/Laboratory, International, Research, HIV/AIDS

The 132nd Annual Meeting (November 6-10, 2004) of APHA

Exhibitor Index or Exhibitors by Category



(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)


gruß werweiß  

   Antwort einfügen - nach oben